/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES/
TORONTO, June 18, 2018 /CNW/ - TerrAscend Corp. (CSE: TER) ("TerrAscend" or the "Company") is pleased to provide an update on its leadership team as the Company continues to expand its operations to support the rapid growth of its medical cannabis business.
Over the past few months, TerrAscend has broadened its Medical Cannabis Leadership Team with the addition of the following key members:
- Sabrina Ramkellawan – Vice President of Clinical Affairs: Sabrina Ramkellawan brings to TerrAscend over 20 years of nursing and clinical research experience for both pharmaceutical and contract research organizations. Her research experience includes conducting both interventional and non-interventional studies on medical cannabis products. She has contributed to the growth of various clinical/operational initiatives, including the start-up of successful cannabis and sleep medicine clinics with a presence across Canada. Ms. Ramkellawan manages Solace Health Network and is responsible for overseeing all clinical research activities.
- Keith Long – Vice President of Sales, Medical: Keith Long has over 25 years of experience supporting the sales efforts of several of the world's largest pharmaceutical companies. Keith spent 17 years with Purdue Pharma in various roles, including Regional Director, Health Solutions, where he led a team of 7 Provincial Business Managers and 47 sales representatives. Mr. Long oversees TerrAscend's medical cannabis sales efforts.
- Dawn Vanek-Mithra – Director of Marketing: Dawn Vanek-Mithra has over 15 years of senior marketing management experience in consumer services, pharmacy, health and wellness. For the last 4 years, Dawn was involved in the cannabis go-to market strategy for both Shoppers Drug Mart pharmacies and Loblaws Companies Limited grocery pharmacies. Ms. Vanek-Mithra manages the Company's medical marketing strategy and brand development.
- Nancy Ciutat – Director of Key Accounts: Nancy Ciutat has over 10 years of combined sales and business development experience in traditional pharma and medical cannabis. For the last year, Nancy has held the role of Sales and Marketing Director for GrowWise Health & Emblem Cannabis, where she was directly responsible for patient recruitment strategies, educational packages and KPI development. Ms. Ciutat oversees key account management to further the Company's medical sales capabilities.
Resignation of Chief Strategy Officer: Vijay Sappani, TerrAscend's co-founder and Chief Strategy Officer, has resigned from his role with TerrAscend effective June 13, 2018. As a co-founder, Mr. Sappani has played a substantial role in the Company's growth for more than four years. TerrAscend and its board of directors would like to thank Mr. Sappani for all of his contributions. In mutual agreement with TerrAscend, Mr. Sappani has agreed to sell 300,000 of his shares of TerrAscend to JW Opportunities Master Fund, Ltd. The Fund is managed by Jason Wild, the Chairman of the Board of Directors at TerrAscend.
TerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. The Company provides support to medical consumers through its wholly-owned subsidiaries, Solace Health Inc., a licenced producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations and Solace Health Network Inc., a clinical support program and education platform led by healthcare professionals.
Forward Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Although TerrAscend believes that the experience of its officers and directors, current conditions and expected future developments and other factors have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because TerrAscend can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release. TerrAscend undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of TerrAscend, its securities, or financial or operating results (as applicable). TerrAscend disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.